Clinician Perceptions of Care Difficulty, Quality of Life, and Symptom Reports for Lung Cancer Patients An Analysis from the Symptom Outcomes and Practice Patterns (SOAPP) Study

Journal of Thoracic Oncology

Volumn 8, Issue 12, 2013, Pages 1474-1483

  Hamann, Heidi A ^a   Lee, Ju Whei ^b   Schiller, Joan H ^a   Horn, Leora ^c   Wagner, Lynne I ^d   Chang, Victor Tsu Shih ^e   Fisch, Michael J ^f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

Care difficulty; Lung cancer; Nihilism; Quality of life; Symptom reports

Indexed keywords

ADULT; ADVANCED PRACTICE NURSE; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; COLON CANCER; COLORECTAL CANCER; COMORBIDITY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HEALTH PERSONNEL ATTITUDE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NURSE PRACTITIONER; OUTCOME ASSESSMENT; PATIENT CARE; PERCEPTION; PHYSICIAN ASSISTANT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RESIDENT; SECONDARY ANALYSIS; WEIGHT GAIN; WEIGHT REDUCTION; CLINICAL PRACTICE; LUNG NEOPLASMS; METASTASIS; PHYSICIAN; PROGNOSIS; PSYCHOLOGY; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ATTITUDE OF HEALTH PERSONNEL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT CARE; PERCEPTION; PHYSICIANS; PRACTICE PATTERNS, PHYSICIANS'; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84892372709     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000437501.83763.5d     Document Type: Article

References (28)

1. Bellizzi KM, Rowland JH, Jeffery DD, McNeel T. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol 2005;23:8884-8893.
2. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005;172:523-529.
3. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008;3:819-831.
4. Ball DL, Irving LB. Are patients with lung cancer the poor relations in oncology? Med J Aust 2000;172:310-311.
5. Perez EA. Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer. Chest 1998;114:593-604.
6. Delaney GP, French BG. Decision-making in lung cancer. In Syrigos KN, Nutting CM, Roussos C (Eds.), Tumors of the Chest: Biology, Diagnosis and Management. New York: Springer, 2006. Pp. 661-677.
7. Rengan R, Hahn SM. Introduction: non-small-cell lung cancer and pleural malignancies: the end of the era of therapeutic nihilism? Semin Radiat Oncol 2010;20:147-148.
8. Zwitter M. Comments on treatment strategy for locally advanced non-small cell lung cancer. Lung Cancer 2002;38(Suppl 3):S33-S35.
9. Gulyn LM, Youssef F. Attribution of blame for breast and lung cancers in women. J Psychosoc Oncol 2010;28:291-301.
10. Gritz ER, Sarna L, Dresler C, Healton CG. Building a united front: aligning the agendas for tobacco control, lung cancer research, and policy. Cancer Epidemiol Biomarkers Prev 2007;16:859-863.
11. Chambers SK, Dunn J, Occhipinti S, et al. A systematic review of the impact of stigma and nihilism on lung cancer outcomes. BMC Cancer 2012;12:184.
12. Wassenaar TR, Eickhoff JC, Jarzemsky DR, Smith SS, Larson ML, Schiller JH. Differences in primary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer. J Thorac Oncol 2007;2:722-728.
13. Fisch MJ, Lee J, Weiss MG, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 2012;30: 1980-1988.
14. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg, CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
15. Maemondo M, Inoue A, Kobayashi K, et al; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
16. Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol 2010;40:101-106.
17. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
18. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
19. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368: 2385-2394.
20. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-1012.
21. Hamann HA, Ostroff JS, Marks EG, et al. Stigma among patients with lung cancer: a patient-reported measurement model. Psycho-Oncology In Press
22. Jennens RR, de Boer R, Irving L, et al. Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer. Chest 2004;126:1985-1993.
23. Stinchcombe TE, Detterbeck FC, Lin L, Rivera M P, Socinski MA. Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer. J Thorac Oncol 2007;2:819-826.
24. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;26:3860-3866.
25. Saito AM, Landrum MB, Neville BA, Ayanian JZ, Earle CC. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care 2011;10:14.
26. Curran WJ Jr, Schiller JH, Wolkin AC, Comis RL; Scientific Leadership Council in Lung Cancer of the Coalition of Cancer Cooperative Groups. Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. Clin Lung Cancer 2008;9:222-226.
27. Klabunde CN, Keating NL, Potosky AL, et al. A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst 2011;103:384-397.
28. Minasian LM, O'Mara AM. Accrual to clinical trials: let's look at the physicians. J Natl Cancer Inst 2011;103:357-358.